Intranasal Steroids Underused in Chronic Rhinosinusitis

This article originally appeared here.
Share this content:
Intranasal Steroids Underused in Chronic Rhinosinusitis
Intranasal Steroids Underused in Chronic Rhinosinusitis

MONDAY, Aug. 29, 2016 (HealthDay News) -- For adult patients with chronic rhinosinusitis (CRS), topical intranasal steroid therapy is underused, with an overall rate of utilization of 20.1 per 100 patients, according to research published online Aug. 25 in JAMA Otolaryngology-Head & Neck Surgery.

Luke Rudmik, M.D., from the University of Calgary in Canada, and colleagues conducted a retrospective review of a Canadian population-based health care administrative database to examine utilization patterns of topical intranasal steroid therapy for CRS. Data were assessed for 19,057 adult patients with CRS.

The researchers found that among patients with CRS, the overall rate of intranasal steroid spray utilization was 20.1 per 100 patients. The mean quantity of utilization was 2.4 U among the 3,821 patients with CRS who used an intranasal spray during 2014 to 2015 (1 U = one bottle per month). Large geographic variation was seen in the rate and quantity of intranasal steroid spray utilization (both P < 0.001).

"Topical intranasal steroid therapy continues to be underutilized for patients with CRS," the authors write. "Given the negative impact of low-quality medical care, outcomes from this study indicate a need to further evaluate factors leading to the underutilization of a recommended treatment in patients with CRS to improve overall health system performance."

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »